Biotech Life Sciences Initiates New Study of Anti-aging Formulas in Helping Covid-19 Post-viral Fatigue and Chronic Fatigue Syndrome

BioTech Life Sciences | August 06, 2020

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.). The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-Viral Fatigue. BioTech specializes in anti-aging, stem cell production and neuroscience, and has discovered a clear link between COVID-19 long-haulers, C.F.S., and the therapeutic benefits of certain anti-aging compounds. According to the Cleveland Clinic and a recent Atlantic article, patients who survive COVID-19 typically recover in roughly two weeks' time. But there are a growing number of patients – as many as 20% – who inexplicably suffer with the disease for months, with longer lasting complications. These so called long-haulers report symptoms including fevers, chest pain, shortness of breath and debilitating fatigue.

Spotlight

One of the criteria for a compound to be considered druggable is the ability to cause or block a biological activity without toxic effects in an in vitro setting using primary human cells. As a read-out for compound-induced activity or toxicity, it is common to determine cell proliferation or cell death.  Proliferation and cytotoxicity can be by looking at ATP levels in the cell. See how ATPlite and ATPlite 1step serve as robust, rapid, high-throughput luminescence assays to quantitatively evaluate proliferation and cytotoxicity in cultured human primary cells.

Spotlight

One of the criteria for a compound to be considered druggable is the ability to cause or block a biological activity without toxic effects in an in vitro setting using primary human cells. As a read-out for compound-induced activity or toxicity, it is common to determine cell proliferation or cell death.  Proliferation and cytotoxicity can be by looking at ATP levels in the cell. See how ATPlite and ATPlite 1step serve as robust, rapid, high-throughput luminescence assays to quantitatively evaluate proliferation and cytotoxicity in cultured human primary cells.

Related News

MEDICAL

Precision NanoSystems is Now a Part of Danaher's Life Sciences Platform

Cytiva, Pall Corporation | June 02, 2021

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danaher Group Executive. "As mRNA has matured as a successful technology in some COVID vaccines, we see huge potential for this technology to accelerate other therapies. The work done thus far by the PNI team will also enable our customers at Cytiva and Pall to take a huge step forward in advancing their science to improve the lives of patients." James Taylor, co-founder, and CEO of Precision NanoSystems, says: "Over the last ten years, PNI has been a leading technology company, enabling the development of genetic medicines. Joining Danaher's Life Sciences platform allows our world-class team to accelerate and expand the work we do to support our customers with comprehensive technology platforms and the expertise to manufacture transformative medicines for the benefit of humanity. With the global reach of the Danaher Life Sciences platform and customers who are leaders in biotechnology, this is an incredible opportunity to bring PNI's innovations to market and expand our impact." The overall mRNA therapeutics and vaccines market was growing rapidly and accelerated with the development of COVID-19 mRNA vaccines. It is anticipated that mRNA technology will be used to develop other vaccines and to treat other conditions of high unmet medical need, such as cancer and genetic diseases. At present, most mRNA therapies and other types of genetic medicines in clinical development are designed to be delivered with the help of lipid nanoparticles (LNPs). PNI's Genetic Medicine Toolkit, including its proprietary GenVoyTM LNP delivery platform and NanoAssemblrTM microfluidic-based nanoparticle manufacturing platform, enables the rapid development of genetic medicines. PNI's validated technologies increase the stability, efficacy, yield, and quality of non-viral genetic medication and lower the barrier to develop these essential medicines. PNI is developing a new center of manufacturing excellence in Vancouver, which will proceed as planned. When complete, the biomanufacturing center will further advance Canadian therapeutic and vaccine manufacturing capabilities, broaden the domestic life sciences sector, create new jobs in the region, and foster a new generation of scientific talent. About Pall Pall Corporation may be a filtration, separation, and purification leader providing solutions to meet customers' critical fluid management needs across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety, and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. About Cytiva Cytiva is a global life science leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency, and capacity to research and manufacture workflows, enabling the development, manufacture, and delivery of transformative medicines to patients.

Read More

AI

Labcorp and PathAI Expand their Partnership to Accelerate Use of AI-Powered Pathology

PathAI, Labcorp | March 09, 2021

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Development. A critical focal point of the extended joint effort will be to empower, in planned clinical trials of cancer and different diseases, the seamless deployment of PathAI's algorithms in the expansive arrangement of projects oversaw by Labcorp Drug Development. These PathAI algorithms are created utilizing Good Clinical Laboratory Practice (GCLP) rules and cycle controls and are bolted and validated as fit for reason; they can likewise be additionally reached out to companion diagnostic (CDx) gadget development and commercialization. They can be sent in review or imminent clinical trials to evaluate tissue-based biomarkers and can uphold patient stratification and selection. The algorithms have numerous potential extra uses where robust deployment and information assortment are required. Labcorp and PathAI plan to investigate connecting the utilization of AI-powered algorithms from translational research into a clinical laboratory setting. “We are very impressed with the vision that Labcorp has for the future of AI-powered pathology in drug development and diagnostics, and we look forward to joining forces to enable our bio-pharma partners to obtain the most accurate, standardized, and data-rich set of pathology readouts from clinical trials to help advance drug development,” said PathAI CEO Andy Beck. “After exploring successful initial projects with Labcorp, we are excited to leverage the scale of its network to grow the reach of digital and computational pathology with the goal of ultimately improving patient outcomes.” “It has been great working with PathAI to expand computational pathology applications in oncology and other diseases that have often been resistant to digitization,” said Paul Kirchgraber, M.D., CEO, Labcorp Drug Development. “This collaboration will provide our bio-pharma partners a differentiated understanding of relevant patient characteristics through applying leading AI-driven algorithms to support clinical trials from novel biomarker development through patient stratification and companion diagnostic development.” About PathAI PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. About Labcorp Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp reported revenue of $14 billion in FY2020.

Read More

CELL AND GENE THERAPY

Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB

Bone Therapeutics | November 29, 2021

BONE THERAPEUTICS the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Link Health Pharma Co., Ltd announce the signing of a non-binding term sheet for the global rights for ALLOB, Bone Therapeutics’ allogeneic bone cell therapy. Subject to the fulfillment of customary condition precedents, Bone Therapeutics and Link Health aim to complete the final agreement and to fully execute it by the end of 2021. This new partnership is separate and independent from the existing license agreement signed on October 5, 2020, for the rights to develop, manufacture and commercialize ALLOB in China for Pregene, and in Hong Kong, Macau, Singapore, Taiwan, Thailand and South Korea for Link Health. Bone Therapeutics will continue to work closely in partnership with Link Health and Pregene on all development activities. Link Health will be responsible for all future development, including the ongoing ALLOB TF2 Phase IIb trial and costs related to development, process development (scale up) and manufacturing of ALLOB. The deal will have no immediate direct cash impact, other than support of all development costs, since no upfront payment is foreseen, however, Bone Therapeutics will receive commercial milestone payments of up to €60 million in total and tiered royalties on net sales of up to 25%. “The existing collaboration between Bone Therapeutics, Link Health and Pregene for the development of ALLOB in Asia has progressed swiftly and fully in line with the anticipated schedule. Bone Therapeutics expanding its collaboration with Link Health will allow for the development and potential availability of ALLOB globally for the benefit of patients with high orthopedic unmet medical needs. This deal now enables Bone Therapeutics to concentrate resources and focus more fully on its iMSC platform. We are now utilizing our extensive cell therapy expertise to develop cell and gene therapy products that have strong anti-inflammatory and immunomodulatory properties, for the treatment of acute life-threatening diseases.” Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics “Link Health has now broadened its therapeutic portfolio to address orthopedic unmet medical needs, aiming to be a global leader in this area. We have already several assets in clinical trial and next generation drug-material combo will also part of our efforts. For ALLOB, we believe that the evidence that Bone Therapeutics has already generated supports its potential clinical value for patients in various indications including spinal fusion and difficult fractures.” said Yan Song, PhD, Chief Executive Officer of Link Health. “Our extended collaboration with Bone Therapeutics will further support the global development of ALLOB. This will enable us to progress in delivering novel disease modifying solution for unmet medical needs for orthopedic patients worldwide.” ALLOB is currently being evaluated in a randomized, double-blind, placebo-controlled Phase IIb study in patients with high-risk tibial fractures. This study will assess and compare against placebo, in association with standard of care stabilization surgery, the potential for ALLOB to accelerate fracture healing after 3-months follow-up and prevent late-stage complications. ALLOB will be applied by a single percutaneous injection 24-96 hours post-definitive reduction surgery in patients with fresh tibial fractures at risk of delayed or non-union. About ALLOB ALLOB is Bone Therapeutics’ off-the-shelf allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. To address critical factors for the development and commercialization of cell therapy products, Bone Therapeutics has established a proprietary, optimized production process that improves consistency, scalability, cost effectiveness and ease of use of ALLOB. This optimized production process significantly increases the production yield, generating thousands of doses per bone marrow donation. Additionally, the final ALLOB product is cryopreserved, enabling easy shipment and the capability to be stored at the point of care for easy clinical use. The process will therefore substantially improve product quality, reduce overall production costs, simplify supply chain logistics, increase patient accessibility and facilitate global commercialization. The Company has implemented the optimized production process to produce clinical batches for the ongoing Phase IIb clinical trial in patients with difficult-to-heal tibial fractures. About Link Health Pharma Co., Ltd Link Health is a leading Chinese pharmaceutical company based in Guangzhou, Southern China. Link Health has a well-established team with solid track records in Licensing and local development of innovative medicinal products in China and Asia-Pacific. By its fully controlled subsidiary BioBone BV, Link Health has created a pipeline including 8 assets for global development in orthopedics and pain management. Link Health has its own research laboratories and core technology to lead drug-materials combo research and lead in the disease modifying novel therapy for orthopedic complicated diseases. Link Health has full team to execute registration, clinical development, business and marketing in China, in several Asian territories and in Netherlands in the Europe. About Bone Therapeutics Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a diversified portfolio of cell therapies at different stages ranging from pre-clinical programs in immunomodulation to mid stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation. Bone Therapeutics’ core technology is based on its cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics’ scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company has initiated patient recruitment for the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental. Bone Therapeutics’ cell therapy products are manufactured to the highest GMP portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium.

Read More